)

60 Degrees Pharmaceuticals (SCTP) investor relations material
60 Degrees Pharmaceuticals H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Strategic focus and product overview
Focused on developing and commercializing small molecule therapeutics for vector-borne diseases, with Aracoda approved for malaria prevention since 2018.
Management team responsible for FDA approval remains in place, aiming to expand Aracoda's label to new indications.
Sales of Aracoda began in 2019 but were initially hampered by the pandemic; sales later increased, driven by unexpected demand for chronic babesiosis.
Gross margin stabilized at about 50% as volume increased, with profitability expected at scale.
Patent life for Aracoda extends to February 2035, with potential to reach over $200 million in sales.
Market research and commercial strategy
Market research revealed that up to 70% of sales were for chronic babesiosis, a previously undescribed disease.
Malaria prevention market faces challenges due to lack of vaccines and complex medication regimens, with Aracoda offering a simpler alternative.
Brand recognition is low, but healthcare providers and patients value Aracoda's features; some are willing to pay a premium.
Commercial pilot program includes electronic outreach, inside sales reps, and a co-pay assistance program, with data expected by year-end to inform 2026 scaling decisions.
Babesiosis program and clinical development
Babesiosis shares similarities with malaria and can be transmitted by ticks and blood donation; new FDA-approved diagnostics have improved detection.
Persistent low-level infection is common, especially in immunosuppressed patients, and may contribute to chronic symptoms.
Tefaniquin, Aracoda's active ingredient, has shown efficacy in animal studies and a Yale case series for relapsing babesiosis.
Three targeted clinical trials are underway: a randomized trial in severe cases, an open-label study in high-risk patients, and a chronic babesiosis trial starting in Q4.
The chronic babesiosis trial aims to enroll 100 patients, using broad diagnostic criteria and focusing on fatigue outcomes and diagnostic confirmation.
Next 60 Degrees Pharmaceuticals earnings date

Next 60 Degrees Pharmaceuticals earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage